Anand Patel
@Anand_88_Patel
Leukemia & myeloid malignancy doctor. tweets=mine. RT≠endorsement. He/him
ID:2417458314
https://scholar.google.com/citations?user=kNhjy-MAAAAJ&hl=en 29-03-2014 13:54:02
6,3K Tweets
4,8K Followers
1,2K Following
Informative paper in Blood Journal re achievement of CRh with targeted therapies in AML!
ashpublications.org/blood/article/…
Thrilled to announce I am one of the recipients of the ASH RTAF #ASHAwards ! A huge thank you to mentors Wendy Stock Faubert Mariam Nawas and institutional support from University of Chicago Hematology/Oncology.
It’s MDS and HSCT week!!!🤩 off the press in Blood Journal 👉Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms? ashpublications.org/blood/article-…
A very nice paper in Blood Advances by Dr Wieduwilt on clinical trial endpoints in ALL studies and highlighting the heterogeneity across various Phase II/III studies
ashpublications.org/bloodadvances/…
#MPNSM Check out this amazing work from Seongseok Yun + Nicole Vincellete. Helps explain what may drive 'triple-negative' MF and provides rationale for our IIT using the JAK2/BRD4 inhibitor fedratinib (which can downregulate myc) in proliferative MDS/MPN. aacrjournals.org/bloodcancerdis…
More from Jad Othman et al re NPM1m AML getting intensive therapy!
-FLT3-ITD, DNMT3A, WT1, non-ABD NPM1 assoc w/ MRD+ & worse OS (all but FLT3-ITD assoc w/ relapse in MRD- dz)
-difficult to identify groups benefiting from allo when NPM1 MRD- post 2 cycles
sciencedirect.com/science/articl…